Team Develops Plan to Globally Crowdsource Breakthrough Innovations to End Alzheimer’s
Frustrated by the absence of public urgency and funding to stop Alzheimer’s—and the slow pace of science—a world-class team of scientists and advocates are joining forces to globally crowdsource a new 21st century approach to leapfrog scientific progress and overcome many of the obstacles to stopping this horrific disease.
The call to discover breakthrough new technologies for brain health is intended to activate interest from a broad spectrum of expert and lay innovators worldwide—from fields as wide-ranging as artificial intelligence, bio-technology, precision pharmaceuticals, physics, video games and brain hacking—to focus their talents and ingenuity on detecting the earliest moments of Alzheimer’s.
“With unprecedented global aging, unless Alzheimer’s disease is stopped—and stopped soon—it will become the health, social and financial sinkhole of the 21st century,” said Ken Dychtwald, PhD, Founder and CEO of Age Wave, and a founding member of the Alzheimer’s Breakthrough team.
At the XPRIZE Visioneers Summit in early October, the Alzheimer’s Breakthrough team will present their innovative proposal—in competition with four other teams focused on other global grand challenges including clean air, zero waste mining, cybersecurity and re-imagining democracy—to a group of 300 scientists, academics, visionaries and funders who will determine which of the prize concepts are “certified to launch.”
The original idea of an Alzheimer’s Breakthrough team was conceived by psychologist/gerontologist Dychtwald and Dr. Peter H. Diamandis, Founder and Executive Chairman of the XPRIZE Foundation, in the fall of 2012. Dychtwald was captivated by XPRIZE’s bold and innovative approach to solving some of the biggest problems of our time.
According to George Vradenburg, JD, Co-Founder and Chairman of UsAgainstAlzheimer’s and a founding member of the Alzheimer’s Breakthrough team, “By employing global crowdsourcing and harnessing emerging technologies, we are hoping to unleash a new era of interventions and treatments that would have the best chance of saving lives.”
“If we prevent Alzheimer’s, we’re going to unlock vast amounts of human potential and reduce or eliminate the suffering of tens of millions of victims and their families,” said Philip Edgcumbe, PhD, a 28-year-old Canadian scientist, biomedical engineer, entrepreneur and medical student who is leading the Alzheimer’s team. “There is currently no cure for Alzheimer’s disease, which affects nearly 50 million people worldwide and is expected to triple in the coming decades due to increasing longevity and the global age wave.”
According to Lisa Genova, PhD, a Harvard trained neuroscientist and best-selling author of Still Alice, “If an XPRIZE were launched to tackle Alzheimer’s, it could change the world’s perception of this disease—from hopelessness that it will never be cured to a hopeful expectation that we will soon have a prevention, treatments or even a cure, much as we’ve seen with tuberculosis, typhoid, diphtheria, polio, certain cancers, HIV and heart disease.”
More than 100 leading neuroscientists, advocates and exponential technology experts have contributed their ideas and insights to this process. Team advisors include: Maria Shriver, activist, journalist, former first lady of California; Geoffrey Ling, MD, PhD, former Founding Director of bio-tech at DARPA; Rudi Tanzi, PhD, Professor of Neurology, Harvard University; Reisa Sperling, MD, Professor of Neurology, Harvard Medical School; Ajay Verma, MD, PhD, CMO at United Neurosciences; and Daniel Kraft, MD, Founding Executive Director Exponential Medicine, Singularity University.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00 | Tiedote
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10 | Tiedote
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13 | Tiedote
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00 | Tiedote
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41 | Tiedote
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00 | Tiedote
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme